Northpond Ventures

What Northpond Ventures does

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland, with regional offices in Cambridge, Massachusetts, and San Francisco, California. The firm invests across life sciences, biotechnology, and healthcare technology, primarily at the seed and early stages, and has built a portfolio of more than 50 lead financings that has produced five NASDAQ IPOs (Candel Therapeutics, CAMP4 Therapeutics, 908 Devices, Kyverna, Vigil Neuroscience) and multiple strategic acquisitions by large life-sciences and healthcare acquirers such as Eli Lilly, Labcorp, OraSure Technologies, SCIEX, Donaldson, Paradigm Health, and Best Buy. Northpond manages over $2 billion in committed capital and operates through three integrated vehicles: the Northpond Ventures main fund (capital deployment), Northpond Labs (a wholly-owned research and development affiliate that funds and engages early-stage science at leading academic institutions), and Northpond Builds (a company-formation arm that converts Labs-funded research into investable ventures, handling IP licensing, pipeline strategy, and company formation).

The firm's core technology is a proprietary translation model rather than a software product. Northpond Labs operates long-dated, multi-year institutional alliances — a $12 million five-year engagement with Harvard's Wyss Institute (expanded in May 2026), a five-year program with MIT's School of Engineering, and a five-year collaboration with Stanford Medicine — that fund translational research and create a pipeline of de-risked science. Builds then matures these research engagements into operating companies that the firm can lead-invest. The revenue model follows standard venture economics: management fees on committed capital (~1.5%–2.0% industry standard on $2B AUM implies a $30M–$40M annual fee base) layered with carried interest on profitable realizations. Customers are split between portfolio companies (which receive capital, mentorship, operational support, IP licensing negotiation, and network access) and institutional limited partners, which provide fund commitments in exchange for exposure to science-driven venture returns. GTM motion is relationship-led, executed through direct engagement with founding scientists, academic technology-transfer offices, and the firm's branded Labs/Builds programs rather than through conventional marketing channels.

Name

Northpond Ventures

Legal name

Northpond Ventures, LLC

Website

https://npv.vc

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Northpond Ventures is a Bethesda-based, science-driven venture capital firm with over $2 billion in committed capital, investing in early-stage life sciences and technology companies sourced through its Northpond Labs and Northpond Builds programs at Harvard, MIT, and Stanford.

Ownership category

akta.pro rank

Product category

Venture Capital (Life Sciences and Technology)

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Late-Stage Venture Capital (Series C+) (FSANAAAC)

Keywords

• Venture capital investing
• Life sciences funding
• Biotech venture capital
• Seed-stage science investing
• Translational research funding

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Management Fees and Carried Interest: Northpond Ventures generates revenue through traditional venture capital fund economics, including management fees on committed capital and carried interest (performance fees) on fund returns. The firm manages over $2 billion in committed capital across its funds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Northpond Ventures is a science-driven venture capital firm that deploys capital into early-stage life sciences and technology companies with strong academic origins. It operates an integrated pipeline comprising Northpond Labs, which funds translational research at leading universities, and Northpond Builds, which converts research engagements into seed-stage companies, backed by over $2 billion in committed capital.

Product overview

Northpond Ventures operates as a science-driven venture capital firm with three core offerings: Northpond Ventures (the main VC fund with over $2 billion in committed capital investing in breakthrough science and technology), Northpond Labs (the R&D-focused affiliate that funds early-stage science at academic institutions like Harvard and MIT), and Northpond Builds (the company formation arm that transforms research into investable companies). The firm maintains offices in Bethesda, MD (headquarters), Cambridge, MA, and San Francisco, CA, and has been recognized as one of the most active lead biotech investors.

Differentiator

Problem solved

Functional benefit

Products and services

• Northpond Ventures Fund Science-driven venture capital fund with over $2 billion in committed capital that partners with leading scientists, academics, and entrepreneurs to develop breakthrough life sciences and technology companies.
• Northpond Labs Research and development-focused affiliate that identifies, supports, funds, and engages early-stage science at leading academic institutions, including Harvard, MIT, and Stanford Medicine.
• Northpond Builds Program that transforms research engagements from Northpond Labs into companies ripe for further investment, providing direct support for critical early-stage activities including IP license negotiation, product and pipeline strategy, company formation, and investor network introductions.

Quantifiable outcome

• Over 50 financings led over the past several years with high percentage having academic origin
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and flagship.

• Stanford MedicinecoreStrategic or Co-development Partner · 28 June 2023The Northpond Laboratories – Program for Research and Innovation at Stanford Medicine identifies and builds upon scientific discoveries from Stanford faculty and researchers, accelerating translation from research to clinical and real-world applications through entrepreneurship.
• MIT School of EngineeringcoreStrategic or Co-development Partner · 15 June 2022Five-year MIT-Northpond Program aims to generate applied solutions addressing unmet commercial needs in life sciences. The program funds translational research projects, supports postdoctoral fellows, and aligns Northpond VC investors with MIT scientific entrepreneurs for mentorship and collaboration.
• Harvard Wyss Institute for Biologically Inspired EngineeringflagshipStrategic or Co-development Partner · 18 November 2020Northpond Labs committed $12 million over five years to create the Laboratory for Bioengineering Research and Innovation at the Wyss Institute. The alliance supports impactful research with strong translation potential, including initial focus on Controlled Enzymatic RNA Synthesis technology (now EnPlusOne Biosciences).
• Harvard Office of Technology DevelopmentcoreStrategic or Co-development Partner · 18 November 2020Partnership with Harvard OTD to finalize collaboration agreements and funded research projects, supporting the translation of Wyss Institute discoveries into commercial opportunities.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ARCH Venture Partners: ARCH is a science-driven venture firm that originates and builds companies from academic research, with a similarly heavy focus on biotech and deep tech. Comparable to Northpond in sourcing from leading research institutions and being among the most active lead biotech investors.
• Atlas Venture: Atlas Venture is an early-stage life-sciences VC that builds biotech companies from academic science, closely mirroring Northpond's Labs/Builds model. Both firms focus on seed and Series A biotech creation with deep scientific involvement.
• Versant Ventures: Versant is a dedicated healthcare and life-sciences venture firm investing across stages in biotech, medtech, and diagnostics. Its stage range and sector focus closely overlap with Northpond's investing activity.
• 5AM Ventures: 5AM Ventures is an early-stage science-focused VC that creates and funds biotech companies from academic research. Comparable in thesis (lab-to-company translation) and stage focus to Northpond Labs and Builds.
• Lux Capital: Lux Capital invests in science-driven and deep-tech companies, including substantial biotech and life-sciences exposure. Comparable in science-led thesis, although Lux is broader across hard-tech sectors.
• Third Rock Ventures: Third Rock builds biotech companies from academic science by conceiving and launching ventures internally, closely paralleling Northpond's Labs/Builds pipeline. Both are founder-led firms creating companies around breakthrough science.
• RA Capital Management: RA Capital is a healthcare-focused investment manager that both funds public and private biotech and conducts crossover and venture investing. Comparable in deep biotech specialization and active lead-investor behavior.
• DCVC (Data Collective): DCVC is a science-driven VC investing in deep-tech and computational biology/life-sciences companies. Comparable as a science-led investor with significant biotech and life-sciences exposure, although it spans a broader deep-tech mandate.

Broad incumbents

• Flagship Pioneering: Flagship is a larger, established science-creation platform that both originates biotech ventures internally and funds external innovation. It is comparable as a science-first investor but operates at materially greater scale and scope than Northpond.
• New Enterprise Associates (NEA): NEA is a large, multi-stage venture firm with a substantial life-sciences franchise. It overlaps with Northpond's biotech investing activity but operates across far more sectors and stages at materially greater AUM scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/npv_vc
• LinkedInlinkedin.com/company/northpond-ventures/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments133 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Northpond Ventures